We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ACRO, Drugmakers Request Clearer FDA Guidance on Multiple-Endpoint Trials
ACRO, Drugmakers Request Clearer FDA Guidance on Multiple-Endpoint Trials
Pharmaceutical companies and clinical research organizations are seeking greater clarity in an FDA draft guidance covering clinical trials with multiple endpoints.